For instance, dasatinib was approved to treat chronic myeloid leukemia (Breccia et al., 2013), whereas SRC-based therapy for HNSCC is limited (Lang et al., 2018). The gene discussed is SRC; the disease is chronic myelogenous leukemia, BCR-ABL1 positive.